Pediatr. praxi. 2024;25(2):115-119

Look at erdosteine in the decade since Erica's study

prof. MUDr. František Kopřiva, Ph.D., MUDr. Denis Dvořák
Dětská klinika LF UP a FN Olomouc

In 2013-2015, in cooperation with general practitioners for children and adolescents, the ERICA study was conducted in children with recurrent respiratory tract infections. We hypothesized that when erdosteine is administered in the first days of an incipient infection, the rate of inflammatory response in the respiratory tract will decrease and thus the severity of clinical symptoms and the need for antibiotic treatment. Within ten years, the new properties of erdostein were confirmed in patients with chronic obstructive pulmonary disease and during the SARS-Covid-2 epidemic. Thus, erdostein is not only a mucolytic substance, but has significant antioxidant and anti-inflammatory properties. Over the years, these new findings have supported our hypothesis.

Keywords: erdosteine, mucoactive substance, ERICA, ATB, anti‑inflammatory and antioxidant effect.

Published: April 8, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kopřiva F, Dvořák D. Look at erdosteine in the decade since Erica's study. Pediatr. praxi. 2024;25(2):115-119.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Slíva J. Přínos erdosteinu a jeho použití v kombinaci s jinými léčivy v pneumologii. Farmakoter Revue. 2023;2:151-148.
    2. Lapka M. Aktuální terapeutické možnosti erdosteinu. Prakt. Lékáren. 2021;(17)1:22-24. Go to original source...
    3. Dal Negro RW, Visconti M, Micheletto C, et al. Changes in blood ROS, e‑NO, and some pro‑inflammatory mediators in bronchial secretions following Erdosteine or placebo: A controlled study in current smokers with mild COPD. Pulm Pharmacol Ther. 2008;2:304-308. Go to original source... Go to PubMed...
    4. Dal Negro RW. Erdosteine: antitussive and antiinflammatory effects. Lung 2008;186(Suppl. 1):70-73. Go to original source... Go to PubMed...
    5. Kopřiva F. Sledování ATB léčby dětských pacientů s recidivujícími respiračními infekcemi v letech 2013-2015 a erdosteinu, aneb co nám řekla "ERICA". Vox Pediatriae. 2017;(17)1:42-44. Go to original source...
    6. Otruba L, Salzman R, Kellnerová R, et al. Erdostein u otitis media secretorica. Otorinolaryng Foniat. 2015;2:107-110.
    7. Cazzola M, Page C, Rogliani P, et al. Multifaceted beneficial effects of erdosteine: more than a mucolytic agent. Drugs. 2020;17:1799-1809. Go to original source... Go to PubMed...
    8. Hayashi K, Hosoe H, Kaise T, et al. Protective effect of erdosteine against hypochlorous acid‑induced acute lung injury and lipopolysaccharide‑induced neutrophilic lung inflammation in mice. J Pharm Pharmacol. 2000; 52:1411-1416. Go to original source... Go to PubMed...
    9. Fraňova S, Kazimierova I, Pappova L, et al. The effect of erdosteine on airway defense mechanisms and inflammatory cytokines in the settings of allergic inflammation. Pulm Pharmacol Ther. 2019;54:60-67. Go to original source... Go to PubMed...
    10. Morice A, Moretti M, Ballabio M. Abstract S116. Erdosteine in association with amoxicillin improves the outcome of acute exacerbations compared to amoxicillin alone in COPD patients. Thorax. 2007;62(Suppl 3):A.47.
    11. Boyaci H, Maral H, Turan G, et al. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol Cell Biochem. 2006;281:129-137. Go to original source... Go to PubMed...
    12. Santus P, Tursi F, Croce G, et al. Changes in quality of life and dyspnoea after hospitalization in COVID‑19 patients discharged at home. Multidiscip Respir Med. 2020;15:713. Go to original source... Go to PubMed...
    13. Strizzi S, Danzo F, Vanneti C, et al. Antiviral and antinflammatory effects of Erdosteine and MET-1 in SARS-CoV-2 in vitro infection. ERS International Congress, 9-13 September 2023, Milano, Italy (poster). Go to original source...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.